To identify mutations that confer resistance to CLL targeted treatments with Btk or Bcl2 Inhibitors
Latest Information Update: 03 Oct 2024
At a glance
- Drugs Acalabrutinib (Primary) ; Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 03 Oct 2024 New trial record